Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

Phase 4

Conditions: Type 2 Diabetes
Atherosclerotic Cardiovascular Disease

Interventions: Drug: Rosuvamibe
Drug: Monorova

First Posted Date: 2018-01-18

Last Posted Date: 2020-12-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 140

Registration Number: NCT03403556

Locations: 🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of

and more 3 locations

A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients

Phase 4

Completed

Conditions: Respiratory Disease

Interventions: Drug: YMC026
Drug: Placebo

First Posted Date: 2017-11-07

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 223

Registration Number: NCT03334916

Locations: 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

Phase 4

Completed

Conditions: Dyslipidemia
Hypertension

Interventions: Drug: Telmisartan
Drug: Duowell®

First Posted Date: 2017-08-30

Last Posted Date: 2021-04-06

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 80

Registration Number: NCT03267329

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706

Phase 1

Completed

Conditions: Dyslipidemia
Type 2 Diabetes Mellitus

Interventions: Drug: YHR1705
Drug: YHR1706
Drug: YHR1705+YHR1706

First Posted Date: 2017-08-01

Last Posted Date: 2017-11-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 28

Registration Number: NCT03235362

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Phase 4

Completed

Conditions: Essential Thrombocythemia

Interventions: Drug: Anagre Cap.

First Posted Date: 2017-07-27

Last Posted Date: 2021-07-21

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 70

Registration Number: NCT03232177

Locations: 🇰🇷
Veterans Health Service medical Center, Seoul, Korea, Republic of
🇰🇷
Dongguk University Medical Center, Goyang, Korea, Republic of
🇰🇷
The Catholic University of Korea. ST. Vincents Hospital, Suwon-si, Gyeonggi, Korea, Republic of

and more 17 locations

A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia

Phase 4

Completed

Conditions: Diabetes Mellitus and Hypercholesterolemia

Interventions: Drug: Rosuvastatin
Drug: Rosuvastatin+Ezetimibe

First Posted Date: 2017-07-14

Last Posted Date: 2019-09-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 85

Registration Number: NCT03217409

Locations: 🇰🇷
Soon Chun Hyang University Hospital Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of

and more 1 locations

Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers

Phase 1

Completed

Conditions: Peripheral Neuropathic Pain

Interventions: Drug: YHD1119 300mg

First Posted Date: 2017-06-19

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 24

Registration Number: NCT03191136

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Temisartan/Amlodipine+Rosuvastatin
Drug: YHP1604

First Posted Date: 2017-04-17

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 62

Registration Number: NCT03116516

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Phase 3

Completed

Conditions: Hypertension and Hyperlipidemia

Interventions: Drug: YHR1703
Drug: YHR1704
Drug: YHP1701

First Posted Date: 2017-04-06

Last Posted Date: 2018-09-07

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 106

Registration Number: NCT03103256

Locations: 🇰🇷
Seoul Medical Center, Seoul, Korea, Republic of

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Phase 3

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Temisartan+Rosuvastatin
Drug: Temisartan+Amlodipine+Rosuvastatin (Combination drug)
Drug: Temisartan+Amlodipine

First Posted Date: 2017-03-01

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 202

Registration Number: NCT03067688

Locations: 🇰🇷
Seoul Natuional University Hospital, Seoul, Jongno, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy